Optical Coherence Tomography (OCT) Findings in Post-COVID-19 Healthcare Workers.

Publication date: Jun 12, 2025

Recent evidence suggests that SARS-CoV-2 may induce subtle anatomical changes in the retina, detectable through advanced imaging techniques. This retrospective case-control study utilized optical coherence tomography (OCT) to assess medium-term retinal alterations in 55 healthcare workers, including 25 individuals with PCR-confirmed COVID-19 and 30 non-COVID-19 controls, all of whom had worked in COVID-19 clinical settings. Comprehensive ophthalmological examinations, including OCT imaging, were conducted six months after infection. The analysis considered demographic variables, comorbidities, COVID-19 severity, risk factors, and treatments received. Central macular thickness (CMT) was significantly increased in the post-COVID-19 group (p < 0. 05), with a weak but statistically significant positive correlation between CMT and disease severity (r = 0. 245, p < 0. 05), suggesting potential post-inflammatory retinal responses. No significant differences were observed in retinal nerve fiber layer (RNFL) or ganglion cell complex (GCL + IPL) thickness. However, mild negative trends in inferior RNFL and average GCL+IPL thickness may indicate early neurodegenerative changes. Notably, patients with comorbidities exhibited a significant reduction in superior and inferior RNFL thickness, pointing to possible long-term neurovascular impairment. These findings underscore the value of OCT imaging in identifying subclinical retinal alterations following COVID-19 and highlight the need for continued surveillance in recovered patients, particularly those with pre-existing systemic conditions.

Open Access PDF

Concepts Keywords
Ganglion neurovascular imaging
Oct optical coherence tomography
Ophthalmological post-COVID-19 retinal changes
Pcr
Weak

Semantics

Type Source Name
disease MESH COVID-19
disease MESH infection
disease MESH ganglion
disease IDO cell
disease MESH Long Covid
drug DRUGBANK Rasagiline
disease IDO blood
drug DRUGBANK Isoxaflutole
disease MESH hypertensive retinopathy
disease IDO nucleic acid
disease MESH inflammation
disease MESH thrombosis
disease MESH ischemia
disease MESH retinal vasculitis
disease MESH Diabetes mellitus
disease MESH hypertension
disease MESH respiratory diseases
drug DRUGBANK Trestolone
disease MESH diabetic retinopathy
disease MESH cytokine storm
disease MESH retinal diseases
drug DRUGBANK Sulodexide
disease IDO healthcare facility
disease MESH coma
disease MESH ocular hypertension
disease MESH uveitis
disease MESH refractive error
disease IDO history
drug DRUGBANK Coenzyme M
drug DRUGBANK Hydroxychloroquine
drug DRUGBANK Tocilizumab
drug DRUGBANK Azithromycin
disease IDO symptom
disease MESH conjunctivitis
disease MESH cardiovascular risk factors
drug DRUGBANK Angiotensin II
disease MESH maculopathy
disease MESH acute macular neuroretinopathy
disease MESH central retinal artery occlusion
disease MESH Retinal vein occlusion
disease IDO entity
drug DRUGBANK Etoperidone
disease MESH Death
disease MESH viral load
drug DRUGBANK Guanosine
disease MESH Visual Impairment
disease MESH vascular disease
disease MESH Glaucoma
disease MESH Syndrome
disease MESH COPD
disease MESH macular edema

Original Article

(Visited 1 times, 1 visits today)